Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding

European Journal of Biochemistry

Volumn 268, Issue 4, 2001, Pages 1095-1106

  Wind, Troels ^a   Jensen, Mads A ^a   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Epitope mapping; Monoclonal antibody; PAI 1; Phage display; Vitronectin

Indexed keywords

AMINO ACID DERIVATIVE; CARRIER PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; SERINE PROTEINASE INHIBITOR; VITRONECTIN;

ALPHA HELIX; ARTICLE; BETA SHEET; BINDING AFFINITY; COMPLEX FORMATION; DNA FLANKING REGION; MOLECULAR STABILITY; MUTAGENESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; REGULATORY MECHANISM;

ALANINE; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; EPITOPE MAPPING; EPITOPES; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PEPTIDE LIBRARY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN CONFORMATION; SPECIES SPECIFICITY; VITRONECTIN;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0035059744     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2001.2680041095.x     Document Type: Article

References (56)

1. Structure-function relationships in serpins: Current concepts and controversies
2. Role of vitronectin and its receptors in haemostasis and vascular remodeling
3. The PAI-1/vitronectin interaction: Two cats in a bag?
4. The serpin PAI-1 inhibits cell migration by blocking integrin 3 binding to vitronectin
5. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation
6. The urokinase receptor is a major vitronectin-binding protein on endothelial cells
7. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
8. The role of plasminogen activator inhibitor-1 as inhibitor of platelet and megakaryoblastic cell adhesion
9. Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system
10. The urokinase-type plasminogen activator system in cancer metastasis: A review
11. The plasminogen activation system in tumor growth, invasion, and metastasis
12. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
13. Implications of the three-dimensional structure of α1-antitrypsin for structure and function of serpins
14. The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites
15. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates
16. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism
17. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex
18. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into beta-sheet A
19. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor
20. Structure of a serpin-protease complex shows inhibition by deformation
21. The role of conformational change in serpin structure and function
22. Structural basis of latency in plasminogen activator inhibitor-1
23. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
24. Serpin tertiary structure transformation
25. Type-1 plasminogen-activator inhibitor - Conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility
26. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion
27. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation
28. Localization of a vitronectin binding region of plasminogen activator inhibitor-1
29. Localization of vitronectin binding domain in plasminogen activator inhibitor-1
30. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)
31. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells - Inhibitor neutralization and one-step affinity purification
32. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: Localization of interaction sites and physiologic relevance
33. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms
34. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1)
35. Vitronectin and substitution of a β-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F
36. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator
37. Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies
38. 2-macroglobulin receptor in human breast carcinomas
39. 2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor
40. Plasminogen activator inhibitor type-1: Reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing
41. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism
42. Libraries of peptides and proteins displayed on filamentous phage
43. Isolation of a highly specific ligand for the α5β1 integrin from a phage display library
44. Glycerol diversifies phage repertoire selections and lowers non-specific phage absorption
45. 32P-labeled protein, applied to HIV-1 Gag and Rev
46. Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12
47. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis
48. Filamentous phage display of oligopeptide libraries
49. High resolution functional analysis of antibody - Antigen interactions
50. Protein movement during complex-formation between tissue plasminogen activator and plasminogen activator inhibitor-1
51. The crystal structure of plasminogen activator inhibitor 2 at 2.0 Å resolution: Implications for serpin function
52. 1-antitrypsin is in the canonical inhibitory conformation
53. Crystal structure of ovalbumin as a model for the reactive centre of serpins
54. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule
55. Importance of the Hinge Region between α-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies
56. Characterization of the interaction of plasminogen activator inhibitor type 1 with vitronectin by surface plasmon resonance